The Effect of Urinary Trypsin Inhibitor Against Neuropathic Pain in Rat Models

Overview

Journal Korean J Pain

Date 2013 Oct 25

PMID 24156001

Citations 7

Authors

Ki Tae Jung

Hyun Young Lee

Myung Ha Yoon

Kyung Joon Lim

Affiliations

Soon will be listed here.

Abstract

Background: Nerve injury sometimes leads to chronic neuropathic pain associated with neuroinflammation in the nervous system. In the case of chronic neuropathic pain, the inflammatory and algesic mediators become predominant and result in pain hypersensitivity following nervous system damage. It is well known that urinary trypsin inhibitor (ulinastatin, UTI) has an anti-inflammatory activity. Recently, the neuroprotective action of UTI on the nervous system after ischemic injury has been reported. Thus, we evaluated the neuroprotective effect of ulinastatin in a rat model of neuropathic pain.

Methods: Neuropathic pain was induced with L5 spinal nerve ligation (SNL) in male Sprague-Dawley rats weighing 100-120 g. The rats were divided into 3 groups, with n = 8 in each group. The rats in the control group (group 1) were administered normal saline and those in group 2 were administered UTI (50,000 U/kg) intravenously through the tail vein for 3 days from the day of SNL. Rats in group 3 were administered UTI (50,000 U/kg) intravenously from the 5(th) day after SNL. The paw withdrawal threshold was measured using the von Frey test for 3 days starting from the 5(th) day after SNL.

Results: The paw withdrawal thresholds were significantly increased in the rats of group 2 compared to the other groups (P < 0.05).

Conclusions: Ulinastatin, which was administered for 3 days after SNL, increased the paw withdrawal threshold and it could have a neuroprotective effect in the rat model of neuropathic pain.

Citing Articles

Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.

Puscasu C, Negres S, Zbarcea C, Chirita C Life (Basel). 2024; 14(11).

PMID: 39598298 PMC: 11595627. DOI: 10.3390/life14111500.

Ulinastatin inhibits NLRP3-induced apoptosis in a PD cell model.

Lin Y, Xu D, Gao F, Zheng X Ann Transl Med. 2021; 9(11):924.

PMID: 34350239 PMC: 8263882. DOI: 10.21037/atm-21-1882.

Ulinastatin alleviates traumatic brain injury by reducing endothelin-1.

Liu T, Liao X, Zhou M Transl Neurosci. 2021; 12(1):1-8.

PMID: 33505713 PMC: 7788573. DOI: 10.1515/tnsci-2021-0001.

Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway suppression of nuclear factor-κB.

Oh S, Lee H, Ki Y, Kim S, Lim K, Jung K Korean J Pain. 2020; 33(1):30-39.

PMID: 31888315 PMC: 6944363. DOI: 10.3344/kjp.2020.33.1.30.

Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway.

Ouyang H, Nie B, Wang P, Li Q, Huang W, Xin W Mol Pain. 2016; 12.

PMID: 27175013 PMC: 4956156. DOI: 10.1177/1744806916646785.

References

Lee H, Lee K, Son S, Hwang S, Cho H . Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport. 2004; 15(18):2807-11. View

Thacker M, Clark A, Marchand F, McMahon S . Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. 2007; 105(3):838-47. DOI: 10.1213/01.ane.0000275190.42912.37. View

Park K, Lee K, Kim H, Hwang S . The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci. 2010; 25(1):128-34. PMC: 2800012. DOI: 10.3346/jkms.2010.25.1.128. View

Chung J, Kim H, Chung K . Segmental spinal nerve ligation model of neuropathic pain. Methods Mol Med. 2004; 99:35-45. DOI: 10.1385/1-59259-770-X:035. View

Austin P, Moalem-Taylor G . The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010; 229(1-2):26-50. DOI: 10.1016/j.jneuroim.2010.08.013. View

Zhu W, Yamanaka H, Obata K, Dai Y, Kobayashi K, Kozai T . Expression of mRNA for four subtypes of the proteinase-activated receptor in rat dorsal root ganglia. Brain Res. 2005; 1041(2):205-11. DOI: 10.1016/j.brainres.2005.02.018. View

Park J, Kwak S, Jeong C, Bae H, Kim S . Effect of ulinastatin on cytokine reaction during gastrectomy. Korean J Anesthesiol. 2010; 58(4):334-7. PMC: 2876852. DOI: 10.4097/kjae.2010.58.4.334. View

Dogrul A, Ossipov M, Lai J, Malan Jr T, Porreca F . Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci Lett. 2000; 292(2):115-8. DOI: 10.1016/s0304-3940(00)01458-0. View

Cao L, Wang J, Hao P, Sun C, Chen Y . Effects of ulinastatin, a urinary trypsin inhibitor, on synaptic plasticity and spatial memory in a rat model of cerebral ischemia/reperfusion injury. Chin J Physiol. 2012; 54(6):435-42. DOI: 10.4077/CJP.2011.AMM058. View

10.

Wang X, Xue Q, Yan F, Li L, Liu J, Li S . Ulinastatin as a neuroprotective and anti-inflammatory agent in infant piglets model undergoing surgery on hypothermic low-flow cardiopulmonary bypass. Paediatr Anaesth. 2013; 23(3):209-16. DOI: 10.1111/pan.12073. View

11.

Kim S, Chung J . An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992; 50(3):355-363. DOI: 10.1016/0304-3959(92)90041-9. View

12.

Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A . Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock. 2001; 15(2):101-5. DOI: 10.1097/00024382-200115020-00004. View

13.

Shu Y, Yang Y, Qiu W, Lu Z, Li Y, Bao J . Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis. Neurochem Res. 2011; 36(11):1969-77. DOI: 10.1007/s11064-011-0520-4. View

14.

Uceyler N, Sommer C . Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett. 2008; 437(3):194-8. DOI: 10.1016/j.neulet.2008.03.050. View